KR900016101A - 아미노구아니딘 유도체 - Google Patents

아미노구아니딘 유도체 Download PDF

Info

Publication number
KR900016101A
KR900016101A KR1019890005484A KR890005484A KR900016101A KR 900016101 A KR900016101 A KR 900016101A KR 1019890005484 A KR1019890005484 A KR 1019890005484A KR 890005484 A KR890005484 A KR 890005484A KR 900016101 A KR900016101 A KR 900016101A
Authority
KR
South Korea
Prior art keywords
group
amino
compound
guanidine
methyl
Prior art date
Application number
KR1019890005484A
Other languages
English (en)
Inventor
수이찌 오우찌다
마사아끼 또다
쭈모루 미야모또
Original Assignee
사노 가즈오
오노 야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노 가즈오, 오노 야꾸힝고오교 가부시끼가이샤 filed Critical 사노 가즈오
Publication of KR900016101A publication Critical patent/KR900016101A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음.

Description

아미노구아니딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 일반식 (IA)의 아미노구아니딘 유도체.
    상기식에서, (i)R2a및 R3a는 각각 수소원자이고, -Xa-R1a는 n-부틸, 사이클로헥실, 벤질, 4-클로로벤질, 4-플루오로벤질, 4-메톡시벤질, 4-메틸벤질, 3-니트로벤질, 3, 4-디클로로벤질, 펜에틸, 3-페닐-2-프로페닐 또는 1 -나프틸메틸 그룹 이거나, (ii)R2a는 수소 원자이고,-Xa-R1a는 벤질 그룹이며, R3a는 메틸그룹 이거나, -Xa-R1a및 R3a는 둘다 페닐 그룹이거나, (iii) R3a는 수소 원자이고, -Xa-R1a및 R2a는 둘다 에틸그룹 또는 n -부틸 그룹이거나, -Xa-R1a는 벤질 그룹이고 R2a는 페닐그룹 이거나,-Xa-R1a는 페닐그룹이고 R2a는 메틸그룹 이거나 -Xa-R1a는 벤질 그룹이고 R2a는 메틸 그룹이거나, (iv)R2a및 R3a는 수소 원자 이고,-은 1- 피페리디노, 1-(1,2,3,4-테트라 하이드로)이소퀴놀릴, 1-피롤리디닐, 4-모노폴리노 또는 4- 하이드록시피페리디노 그룹이거나,-은 4- 모르폴리노 그룹이고 R3a는 메틸그룹이 거나,-은 4-하이드록시피페리디노 그룹이고 R3a는 프로필 그룹이거나, (Ⅴ)-Xa-R1a및 R2a는 둘다 수소 원자이고, R3a는 벤질, 펜에틸, 3-페닐프로필, 사이클로펜틸 메틸 또는 2-피라딜 그룹이다
  2. 제1항에 있어서, 1-아미노-3-벤질구아니딘, 1-아미노-3-펜에틸구아니딘, 1-아미노-3-n-부틸구 아니딘, 1-아미노-3-사이클로헥실구아니딘, 1-아미노-3- (4-클로로벤질)구아니딘, 1-아미노-3- (4-플루오로벤질)구아니딘. 1-아미노-3- (4-메톡시 벤질)구아니 딘, 1-아미노-3- (4-메틸 벤질)구아니딘, 1-아미노-3- (1-나프틸메틸)구아니딘, 1-아미노-3- (3-니트로벤질)구아니딘, 1-아미노-3- (3-페닐-2-프로페닐)구아니딘 또는 1-아미노-3- (3,4-디클로벤질)구아니딘인 화합물.
  3. 제1항에 있어서, 1-아미노-1-메틸-3-벤질구아니딘 또는 1-아미노-1-페닐-3-페닐구아니딘인 화합물.
  4. 제1항에 있어서, 1-아미노-3,3-디에틸구아니딘, 1-아미노-3-벤질-3-페닐구아니딘, 1-아미노-3-메틸-3-페닐구아니딘, 1-아미노-3-벤질-3-메틸구아니딘 또는 1-아미노-3,3-디 -n-부틸구아니딘인 화합물.
  5. 제1항에 있어서, 1-피페리딘 카르보하이드라자이드 이미드, 1-(1,2,3,4-테트리하이드로)이소퀴놀린카르보하이드라자이드 이미드. 1-피롤리딘카르보하이드라자이드 이미드, 4-모르폴린카르보하이드라자이드 이미드 또는 1-(4-하이드록시)피페리딘카르보하이드라자이드 이미드인 화합물.
  6. 제1항에 있어서, N′-메틸-4-모르폴린카르보하이드라자이드 이미드 또는 N′-n-프로필-1- (4-하이드록시)피페리딘키르보하이드라자이드 이미드인 화합물.
  7. 제1항에 있어서, 1-아미노-1-펜에틸구아니딘. 1-아미노-1-벤질구아니딘, 1-아미노-1- (3-페닐프로필)구아니딘. 1-아미노-1-사이클로펜틸메틸구아니딘 또는 1-아미노-1- (2-피리딜)구아니딘인 화합물.
  8. 일반식 (II)의 화합물과 일반식 (III)의 화합물을 반응시키거나 일반식 (Ⅳ)의 화합물을 반응시킴을 특징으로하여. 일반식 (IA)의 아미노구아니딘 유도체를 제조하는 방법.
    상기식에서, R1a, R2a,R3a및 Xa는 제1항에서 정의한 바와 같다.
  9. 일반식(IA)의 화합물을 포함하는 일반식 (IB)의 아미노구아니딘 유도체 또는 이의 산 부가 염의 유효량 및 약제학적으로 허용되는 담체 및/또는 제피제를 함유함을 특징으로 하는 약제학적 조성물.
    상기식에서, R1b는 수소 원자, 탄소수 1 내지 6의 알킬 그룹, 탄소수5내지 7의 사이클로알킬 그룹, 또는 할로겐 원자 1내지 3개, 탄소수 1내지 4의 알킬 그룹, 탄소수 1내 지 4의 알콕시 그룹 또는 니트로 그룹에 의해 치환되거나 비치환된 카르보사이클릭 또는 헤테로사이클릭 환이고, Xb는 결합이거나, 탄소수 1내지 4의 알킬렌 그룹 또는 탄소수 2내지 4의 알케닐렌 그룹이며, R3b는 수소 원자, 탄소수 1내지 6의 알킬 그룹 또는 페닐그룹이고, R3b는 수소 원자, 페닐 그룹, 탄소수 1내지 4의 알킬 그룹, 탄소수 7내지 10의 페닐알킬그룹 또는 피리딜 그룹이며,는 질소 원자 또는 질소원자 하나 및 산소 원자 하나를 함유하며, 하이드록시 그룹에 의해 치환되거나 비치환된 탄소수 3내지 10의 헤테로사이클릭 환이고, 단 R2b가 수소 원자이고, -Xb-R1b가 수소 원자, 메틸 그룹, 에틸 그룹 또는 페닐 그룹이며, R3b는 수소원자 또는 메틸 그룹인 화합물은 제외한다.
  10. 제9항에 있어서, 1-아미노-3-푸르푸릴구아니딘 유효량을 함유하는 약제학적 조성물.
  11. 일반식(IB)의 카르바조일 유도체 유효량을 투여함을 특징으로 하여, 노화에 의한 여러가지 당뇨병 합병증 및 질병을 치료하거나 예방하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890005484A 1988-04-26 1989-04-26 아미노구아니딘 유도체 KR900016101A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-101365 1988-04-26
JP10136588 1988-04-26

Publications (1)

Publication Number Publication Date
KR900016101A true KR900016101A (ko) 1990-11-12

Family

ID=14298802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890005484A KR900016101A (ko) 1988-04-26 1989-04-26 아미노구아니딘 유도체

Country Status (3)

Country Link
EP (1) EP0339496A3 (ko)
JP (1) JPH0242053A (ko)
KR (1) KR900016101A (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5514676A (en) * 1984-03-19 1996-05-07 The Rockefeller University Amino-benzoic acids and derivatives, and methods of use
US5114943A (en) * 1984-03-19 1992-05-19 The Rockefeller University Amino-substituted pyrimidines, derivatives and methods of use therefor
US5130324A (en) * 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
ATE191847T1 (de) * 1991-12-16 2000-05-15 Univ Washington Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
US5710181A (en) * 1991-12-16 1998-01-20 Washington University Inhibition of nitric oxide formation in inflammatory bowel disease
US5837738A (en) * 1991-12-16 1998-11-17 Washington University Method of inhibiting nitric oxide formation
ATE183086T1 (de) * 1992-04-15 1999-08-15 Alteon Inc Aminoguanidin-spruehtrocknungsverfahren
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
DE69732796T2 (de) * 1996-10-08 2006-05-04 Kao Corp. Antifaltenmittel
CA2664159C (en) 1998-08-24 2013-06-04 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate
AU2002253432B2 (en) 2001-04-05 2005-03-24 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
JP4564786B2 (ja) * 2004-06-07 2010-10-20 株式会社日本ファインケム １−置換―１―アミノグアニジン又はその塩、及びこれらの製造方法
FR2964381A1 (fr) * 2010-09-07 2012-03-09 Prod Chim Auxiliaires Et De Synthese Nouveaux derives guanidines en serie cinnamique.
JP6148127B2 (ja) * 2013-09-09 2017-06-14 株式会社パーマケム・アジア ピリドキサール・アミノグアニジン誘導体またはそれらの塩、及び、その製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1057092B (de) * 1956-10-01 1959-05-14 Ici Ltd Verfahren zur Herstellung von Aminoguanidinen
GB1048812A (en) * 1963-03-05 1966-11-23 Smith Kline French Lab Substituted amino-guanidines
US3377381A (en) * 1967-08-04 1968-04-09 American Home Prod N'-(1-naphthylmethyl)-n3-aminoguanidine and salt thereof
GB1274668A (en) * 1968-06-10 1972-05-17 Ici Ltd Pesticidal compositions comprising aminoguanidines
AU1592270A (en) * 1969-06-17 1971-12-09 Imperial Chemical Industries Limited Antiviral processes and compositions
JPS5093989A (ko) * 1973-10-25 1975-07-26
JPS55157558A (en) * 1979-05-28 1980-12-08 Tamio Nishimura Monoamidinohydrazone of tricyclic carbonyl compound and its preparation
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4983604A (en) * 1987-11-13 1991-01-08 The Rockefeller University Inhibitors of nonenzymatic cross-linking

Also Published As

Publication number Publication date
EP0339496A2 (en) 1989-11-02
EP0339496A3 (en) 1991-05-08
JPH0242053A (ja) 1990-02-13

Similar Documents

Publication Publication Date Title
KR900016101A (ko) 아미노구아니딘 유도체
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
KR900018073A (ko) 피페라진 화합물
KR900014361A (ko) 니코틴산 유도체 및 이를 함유하는 약제학적 조성물
AR002257A1 (es) Compuesto 1h-imidazol util como agente anti-isquemico cardiaco o agente anti-hipertensivo. procedimiento para su preparacion y composicion farmaceuticaque lo contiene.
CA2394086A1 (fr) Derives de 4-aminopiperidine et leur utilisation en tant que medicament
RU94016183A (ru) Производные пиперазина
KR890013044A (ko) Pt(IV)착화합물
KR900016220A (ko) 매크로리드 조성물
RU96123116A (ru) Амиды n-сульфонил- и n-сульфониламинокислот в качестве микробицидов
KR920009791A (ko) 1-(2-아릴에틸)-피롤리딘
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
PT779284E (pt) Novos derivados de 2-naftamidas e suas aplicacoes terapeuticas como agonistas dos receptores d3
KR910000730A (ko) N-헤테로아릴-푸린-6-아민, 이의 제조방법 및 약제로서의 이의 용도
KR870008836A (ko) 디페닐-메탄 유도체 및 제약상 용도
DK173553B1 (da) Aminosyrederivater, antikonvulsant præparat som indeholder aminosyrederivat samt anvendelse af aminosyrederivater til frems
ATE92316T1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR890011872A (ko) 인돌일 피페리딘 화합물, 그 제조방법 및 그들을 함유하는 약학조성물
GB1583211A (en) Permanent wawing
Stone et al. Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species
KR960704541A (ko) 유일한 치료제로서의 히드록실 이온 및 이 이온을 조정하는 화합물, 이 제제를 사용한 조성물, 이 제제를 사용하는 치료 방법 및 이의 제조 방법(Hydroxyl lons as Unique Therapeutic Agents and Compounds that Modulate These Ions, Compositions Employing These Agents, Therapeutic Methods for Using Such Agents and Processes for Preparing Them)
NZ201217A (en) N-(2-aryl-2-hydroxyethyl)-n-(omega-(amino or cyano)alkoxyphenyl)
HUP9904659A2 (hu) Aril-karbonsav- és tetrazolszármazékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid